• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Avalo Therapeutics Purchases Optional Milestone Buyout

    GLOBENEWSWIRE

    Avalo Therapeutics Reveals 2025 Financials And Business Updates

    GLOBENEWSWIRE

    Avalo Therapeutics Joins Upcoming Investor Conferences

    GLOBENEWSWIRE

    Avalo Therapeutics Completes AVTX-009 Phase 2 LOTUS Trial

    GLOBENEWSWIRE

    Avalo Therapeutics Appoints Kevin R. Lind To Board Of Directors

    GLOBENEWSWIRE

    Avalo Therapeutics to Join Investor Conferences

    GLOBENEWSWIRE

    Avalo Therapeutics to Join Investor Conferences

    GLOBENEWSWIRE

    Tango dances away from preclinical work to extend cash runway

    FIERCE BIOTECH

    Avalo Reports Q1 2025 Financial Results and Business Updates

    GLOBENEWSWIRE

    Avalo Therapeutics at Citizens Life Sciences Conference

    GLOBENEWSWIRE

    Avalo Therapeutics to Participate in Upcoming Investor Conferences

    GLOBENEWSWIRE

    Avalo Therapeutics to Present at Oppenheimer Annual Conference

    GLOBENEWSWIRE

    Avalo Therapeutics Appoints Jennifer as Chief Strategy Officer

    GLOBENEWSWIRE

    Avalo Therapeutics Raises $69.4 Million in Private Placement

    GLOBENEWSWIRE

    Avalo Therapeutics to Present at Upcoming Investor Conferences

    GLOBENEWSWIRE

    Avalo Reports Q3 2024 Financial Results & Recent Business Updates

    GLOBENEWSWIRE

    Avalo Doses First Patient In AVTX-009 Phase 2 LOTUS Trial

    GLOBENEWSWIRE

    Avalo Announces Participation in September Investor Conferences

    GLOBENEWSWIRE

    Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

    GLOBENEWSWIRE

    Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002

    GLOBENEWSWIRE

    Avalo Announces Enrollment of 80 Patients in PII PEAK Trial of AVTX-002

    GLOBENEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.